CJC-1295 with DAC

CJC-1295 with DAC (Drug Affinity Complex) is a modified version of growth hormone releasing hormone (GHRH) engineered for extended duration. The addition of DAC technology extends the half-life to 6-8 days, providing continuous growth hormone elevation rather than pulsatile release. This long-acting formulation offers convenience but differs significantly from natural GH secretion patterns.

• Sustained GH Elevation
• IGF-1 Optimization
• Convenience Protocol

Convenient weekly dosing, sustained GH/IGF-1 elevation, significant body composition changes

DAC technology binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation

Peak plasma concentration: 2 hrs. Elimination half-life: 6 days – 8 days. Largely cleared by: 30 days – 40 days.

Research protocols from published literature — not dosing recommendations.

• Ipamorelin — Use Caution: Can be combined but continuous GH elevation from DAC version may reduce synergistic benefits of pulsatile protocols
• GHRP-6 — Use Caution: GHRP pulse effects are diminished when combined with continuous GH elevation from CJC-1295 DAC
• CJC-1295 — Avoid Combination: Never combine different CJC-1295 variants - choose based on desired release pattern
• MK-677 — Avoid Combination: Both provide continuous GH elevation - combination may lead to excessive and unnatural GH levels
• Tesamorelin — Avoid Combination: Both target GHRH receptors but with conflicting release patterns. Tesamorelin promotes pulsatile GH release while DAC provides continuous stimulation, disrupting natural GH rhythms and accelerating receptor downregulation.
• HGH — Avoid Combination: Combining with exogenous HGH defeats the purpose and may suppress natural production
• Sermorelin — Use Caution: Both work through GHRH pathway - CJC-1295 DAC is already more potent and long-lasting

Supplies:

• CJC-1295 with DAC peptide vial
• Bacteriostatic water (2-5mL)
• Insulin syringes or 1mL syringes
• Alcohol prep pads
• Sterile mixing needle

1. 1Clean both vial tops with alcohol and let dry completely
2. 2For 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL concentration)
3. 3For 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL concentration)
4. 4Inject water very slowly to prevent foaming - DAC peptides foam easily
5. 5Let sit for 5 minutes before gently rolling to mix
6. 6Solution may appear slightly cloudy initially but should clear
7. 7Label with date and concentration immediately

Week 1: Possible water retention, improved sleep, increased appetite. Week 2-3: Noticeable recovery improvements, some report joint discomfort. Week 4-6: Visible body composition changes, increased vascularity. Week 6-8: Continued improvements but watch for desensitization signs. Post-cycle: Maintain most gains, IGF-1 returns to baseline in 2-3 weeks.

Higher side effect incidence than pulsatile protocols. Common: Water retention, joint pain, carpal tunnel symptoms. Monitor for signs of excessive GH: jaw growth, hand/feet enlargement. Not suitable for those with diabetes or cancer history. May worsen sleep apnea in predisposed individuals. Regular IGF-1 monitoring recommended for long-term use.

Higher side effect incidence than pulsatile protocols. Common: Water retention, joint pain, carpal tunnel symptoms. Monitor for signs of excessive GH: jaw growth, hand/feet enlargement. Not suitable for those with diabetes or cancer history. May worsen sleep apnea in predisposed individuals. Regular IGF-1 monitoring recommended for long-term use.

CJC-1295 with DAC should be stored at Refrigerate immediately, more stable than non-DAC - use within 60 days.